Back to discover

Protein / target

Hepatocyte nuclear factor 1-alpha

Encoded byHNF1AP20823Homo sapiensSwiss-Prot
UniProt: P20823Ensembl: ENSG00000135100HGNC: HGNC:11621NCBI Gene: 6927
Degrader-tractable
Druggability
UniProt Ubiquitination
2
Research papers

Protein at a glance

Biological role

Transcription cis-regulatory region binding

Strongest disease association

MODY

Via encoding gene HNF1A · Genetic evidence · score 0.94

Research activity

Emerging research

2 papers · latest 2023

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Transcriptional activator that regulates the tissue specific expression of multiple genes, especially in pancreatic islet cells and in liver.

View complete UniProt function annotation

Transcriptional activator that regulates the tissue specific expression of multiple genes, especially in pancreatic islet cells and in liver (By similarity). Binds to the inverted palindrome 5'-GTTAATNATTAAC-3' (PubMed:10966642, PubMed:12453420). Activates the transcription of CYP1A2, CYP2E1 and CYP3A11 (By similarity)

Subcellular location

Nucleus
Domains and Gene Ontology detail (26)

Domains & features

HNF-p1POU-specific atypical

Gene Ontology

  • Cchromatin
  • Ccytoplasm
  • Cnucleus
  • Cprotein-containing complex
  • FDNA binding
  • FDNA-binding transcription activator activity, RNA polymerase II-specific
  • FDNA-binding transcription factor activity
  • FDNA-binding transcription factor activity, RNA polymerase II-specific
  • Fprotein dimerization activity
  • Fprotein heterodimerization activity
  • Fprotein homodimerization activity
  • FRNA polymerase II cis-regulatory region sequence-specific DNA binding

631 aa · 67 kDa · 8 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Transcriptional regulationUniProt · GO
View supporting evidence

Transcriptional regulation

  • ·Transcriptional activator that regulates the tissue specific expression of multiple gene…
  • ·DNA-binding transcription activator activity, RNA polymerase II-specific
  • ·DNA-binding transcription factor activity
  • ·DNA-binding transcription factor activity, RNA polymerase II-specific

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene HNF1A

Gene-level evidence surfaced through the gene HNF1Athat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

MODY
0.97Well supported

Genetic evidence dominant · Open Targets 0.84

Coronary Artery Disease
0.93Well supported

Genetic evidence dominant · Open Targets 0.58

Cholelithiasis
0.92Well supported

Genetic evidence dominant · Open Targets 0.56

Diabetes Mellitus, Type 2
0.92Well supported

Genetic evidence dominant · Open Targets 0.78

Diabetes Mellitus
0.90Well supported

Genetic evidence dominant · Open Targets 0.73

View evidence synthesis (5)
MODYWell supported
0.97
agreement 0.87–1.00
Genetic66%Animal model16%Somatic mutation9%Literature8%Genetic literaturedup

Open Targets aggregate 0.84 · 4 independent evidence families · 1 not counted as duplicate

Coronary Artery DiseaseWell supported
0.93
agreement 0.79–1.00
Genetic89%Literature11%

Open Targets aggregate 0.58 · 2 independent evidence families

CholelithiasisWell supported
0.92
agreement 0.78–1.00
Genetic98%Literature2%

Open Targets aggregate 0.56 · 2 independent evidence families

Diabetes Mellitus, Type 2Well supported
0.92
agreement 0.81–1.00
Genetic75%Somatic mutation13%Literature12%Genetic literaturedup

Open Targets aggregate 0.78 · 3 independent evidence families · 1 not counted as duplicate

Diabetes MellitusWell supported
0.90
agreement 0.78–1.00
Genetic74%Animal model14%Literature12%

Open Targets aggregate 0.73 · 3 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
MODY0.84
Diabetes Mellitus, Type 20.78
Diabetes Mellitus0.73
Diabetes Mellitus, Type 10.69
Coronary Artery Disease0.58
Cholelithiasis0.56

Tractability

Protein degraders — Emerging

Feasibility evidence (uniprot ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (1)
PR · UniProt Ubiquitination

Raw Open Targets tractability assessment buckets, by modality.

Research activity

2 papers · to 2023

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection.776 cites

Alfei F · Nature · 2019

Spatial predictors of immunotherapy response in triple-negative breast cancer.251 cites

Wang XQ · Nature · 2023

Recent

Spatial predictors of immunotherapy response in triple-negative breast cancer.

Wang XQ · Nature · 2023

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection.

Alfei F · Nature · 2019

Europe PMC papers linked directly to this protein.